Korean J Endocr Surg.
2013 Mar;13(1):1-7. 10.0000/kjes.2013.13.1.1.
Surgical Methods for Radioiodine Refractory Thyroid Cancer
- Affiliations
-
- 1Department of Surgery, Pohang St. Mary's Hospital, Pohang, Korea.
- 2Department of Surgery, Ajou University School of Medicine, Suwon, Korea. sohey@ajou.ac.kr
- KMID: 2375412
- DOI: http://doi.org/10.0000/kjes.2013.13.1.1
Abstract
- Most patients with thyroid cancer (of follicular cell origin) are successfully managed with a combination of surgery, radioactive iodine (131I-RAI), and suppression of thyroid-stimulating hormone with thyroid hormone replacement, obtaining survival rates approaching 90% at 20 years. Although the prognosis of patients with differentiated thyroid carcinoma (DTC) is favorable, recurrence occurs in up to 30% patients. In addition, many patients with recurrent or metastatic disease, as well as those with less differentiated tumors, will have a much poorer prognosis and lose their ability to concentrate functional iodine and are therefore not targeted by 131I-RAI therapy. There are many treatment options but no definitive treatment for radioiodine refractory thyroid cancer. This paper will discuss the roles of surgical treatment for patients with radioiodine refractory thyroid cancer.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
- Management of Severe Fatigue Induced by Tyrosine Kinase Inhibitor in Radioiodine Refractory Thyroid Cancer
- Low Dose versus High Dose Radioiodine Therapy
- Management of Bleeding Induced by Tyrosine Kinase Inhibitor in Radioiodine Refractory Thyroid Cancer
- Successful Treatment of Cavernous Sinus Metastasis from Follicular Thyroid Carcinoma with Lenvatinib
